Home » Topics » Disease categories and therapies » Endocrine/metabolic

Endocrine/metabolic
RSS

BioTime reports preliminary phase III data from Hextend trial

Dec. 9, 1997

Lilly discovers highly potent and selective NPY Y1 receptor antagonists

Dec. 9, 1997

NPS and SmithKline Beecham sign additional extension of osteoporosis agreement

Dec. 9, 1997

HMR begins phase II trial with GA-EPO

Dec. 8, 1997

Sanofi in-licenses antidiabetic drug from Bayer

Dec. 4, 1997

New inhibitor of inflammatory bone resorption presented at Tokyo congress

Dec. 4, 1997

Vitronectin receptor antagonists described by Hoechst

Dec. 4, 1997

Bayer develops CETP inhibitors

Dec. 4, 1997

Intermittent therapy with 5-HT reuptake inhibitor effective for dysphoric PMS

Dec. 3, 1997

Mechanism of renoprotective effects of ACE inhibitors in diabetic nephropathy

Dec. 3, 1997

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...